Underreporting and missed opportunities for uptake of intermittent preventative treatment of malaria in pregnancy (IPTp) in Mali

listen audio

Study Justification:
The study aims to identify factors contributing to the low uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) in rural Mali. This is important because malaria in pregnancy can have serious health consequences for both the mother and the unborn child. Understanding the reasons for low uptake can help inform strategies to improve coverage and ultimately reduce the burden of malaria in pregnant women.
Study Highlights:
1. Secondary data analysis found that reported IPTp-SP coverage estimates are misleading due to missing data points.
2. Among women who gave birth in the two years prior to the survey, 56.2% reported taking at least one dose of IPTp-SP.
3. Qualitative data revealed that many health centers do not administer IPTp-SP through directly observed therapy or provide it free of charge.
4. Women generally reported IPTp-SP as available and tolerable, but frequently could not identify its name or purpose accurately.
Study Recommendations:
1. Increasing antenatal care (ANC) attendance should be a priority for increasing IPTp-SP coverage.
2. Reducing cost and access barriers to IPTp-SP.
3. Ensuring that health providers follow up-to-date guidelines for IPTp-SP administration.
4. Improving patient counseling on IPTp-SP to enhance understanding and accurate reporting.
Key Role Players:
1. Ministry of Health: Responsible for implementing policies and guidelines related to malaria prevention in pregnancy.
2. Health facility administrators: Ensure that health centers have the necessary resources and systems in place to provide IPTp-SP.
3. Health providers: Responsible for administering IPTp-SP and providing counseling to pregnant women.
4. Community leaders: Play a role in promoting ANC attendance and raising awareness about the importance of IPTp-SP.
Cost Items for Planning Recommendations:
1. Training and capacity building for health providers on IPTp-SP administration and counseling.
2. Procurement and distribution of IPTp-SP drugs.
3. Health system strengthening to ensure availability of IPTp-SP at health centers.
4. Community engagement and awareness campaigns to promote ANC attendance and IPTp-SP uptake.

The strength of evidence for this abstract is 8 out of 10.
The evidence in the abstract is strong, but there are some areas for improvement. The abstract provides clear objectives, methods, and results. The authors conducted secondary data analysis on Mali’s 2012-2013 Demographic and Health Survey (DHS) and also conducted qualitative interviews, focus groups, and ANC observations in rural sites in Mali’s Sikasso and Koulikoro regions. The results of the secondary data analysis revealed that reported IPTp-SP coverage estimates are misleading due to missing data points. The qualitative data provided insights into the reasons for missed opportunities. The abstract concludes with actionable steps to improve IPTp-SP coverage, such as increasing ANC attendance, reducing cost and access barriers, ensuring providers follow guidelines, and improving patient counseling. However, the abstract could be improved by providing more specific details about the sample size and demographics of the participants in the qualitative interviews, focus groups, and ANC observations. Additionally, it would be helpful to include information about the limitations of the study and any potential biases in the data collection process.

Objectives: To identify factors contributing to low uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) in rural Mali. Methods: We conducted secondary data analysis on Mali’s 2012-2013 Demographic and Health Survey (DHS) to determine the proportion of women who failed to take IPTp-SP due to ineligibility or non-attendance at antenatal care (ANC). We also identified the proportion who reported taking other or unknown medications to prevent malaria in pregnancy and those who did not know if they took any medication to prevent malaria in pregnancy. We conducted qualitative interviews, focus groups and ANC observations in six rural sites in Mali’s Sikasso and Koulikoro regions to identify reasons for missed opportunities. Results: Our secondary data analysis found that reported IPTp-SP coverage estimates are misleading due to their dependence on a variable (“source of IPTp”) that is missing 62% of its data points. Among all women who gave birth in the two years prior to the survey, 56.2% reported taking at least one dose of IPTp-SP. Another 5.2% reported taking chloroquine, 1.9% taking another drug to prevent malaria in pregnancy, 4.4% not knowing what drug they took to prevent malaria, and 1.1% not knowing if they took any drug to prevent malaria. The majority of women who did not receive IPTp-SP were women who also did not attend ANC. Our qualitative data revealed that many health centers neither administer IPTp-SP by directly observed therapy, nor give IPTp-SP at one month intervals through the second and third trimesters, nor provide IPTp-SP free of charge. Women generally reported IPTp-SP as available and tolerable, but frequently could not identify its name or purpose, potentially affecting accuracy of responses in household surveys. Conclusion: We estimate IPTp-SP uptake to be significantly higher than stated in Mali’s 2012-13 DHS report. Increasing ANC attendance should be the first priority for increasing IPTp-SP coverage. Reducing cost and access barriers, ensuring that providers follow up-to-date guidelines, and improving patient counseling on IPTp-SP would also facilitate optimal uptake.

Using the 2012–2013 Mali DHS maternal health dataset in Stata version 12 [23], we ran cross tabulations at each point where a woman could miss an opportunity to take or report having taken IPTp. First, we filtered out women who never attended ANC and those who attended only during their first trimester (prior to IPTp eligibility). Next, we examined the proportion of women who reported that they (a) took at least one dose of IPTp-SP, (b) took chloroquine as IPTp, (c) took an unknown drug to prevent malaria in pregnancy, (d) took another drug for to prevent malaria in pregnancy, (e) did not know if they took any drug to prevent malaria in pregnancy, and (f) did not take any drug to prevent malaria in pregnancy. Among women who reported having taken IPTp-SP1 and were eligible for a IPTp-SP2 (those who had two or more ANC visits after their first trimester), we identified the proportion who reported that they (a) took the second dose, (b) did not take the second dose, and (c) did not know if they took the second dose. To be consistent with the DHS report, we restricted analysis to women who gave birth in the two years prior to the survey. For each analysis, we examined the national sample, and the subset of women from rural areas. All statistics were weighted using DHS methodology [24]. We conducted 28 in-depth interviews (IDIs), 26 focus-group discussions (FGDs) and 29 ANC observations across six rural health zones across Sikasso and Koulikoro. These two regions offer advantages in the study design as they are geographically different from where similar studies have been conducted before (Segou) [11,12], yet have similar IPTp uptake estimates to the national averages [8]. We began by purposively selecting two rural health zones within each region, one served by a larger health center accessible by paved road in a central town or population center, and another served by a smaller health center deep in a rural village and far from a population center or paved road. Within these sites, we purposively sampled community members who could offer a range of perspectives on IPTp, including pregnant women, family members, health workers and community leaders (Table 2). * Numbers presented refer to number of focus groups, not number of participants. We determined we had reached data saturation in IDIs and FGDs with community members in the original four sites, as iterative analysis revealed recurring, developed themes both within and between sites [25,26]. However, because procedures for administering IPTp-SP differed significantly in each of the first four health facilities we observed, we decided to observe additional sites to better characterize that variability. Thus, we added one additional observation site per region. We also determined that themes regarding health system factors warranted triangulation from higher-level health officials. Thus, we added six key informant interviews with leaders at district- and regional-level reference hospitals toward the end of the study. The data collection team included four Malian women trained in qualitative research methods (one sociologist and three physicians) and the first author, an American doctoral student fluent in Bambara. IDIs and FGDs with community members were semi-structured and included topics on a) health, illness prevention and use of medications during pregnancy, b) experiences with ANC and IPTp-SP, and c) perceived barriers to IPTp-SP uptake. The original English versions of the IDI and FGD guides are included as an appendix (S1 Appendix). During key informant interviews, district and regional level health officials were asked about content and implementation of IPTp-SP policy and their views on factors contributing to uptake. The original English versions of the IDI and FGD guides are included as an appendix. IDIs and FGDs were conducted in Bambara, the local language, with the exception of some key informants and clinicians who preferred French. Participants were interviewed in private locations within the community (typically, the participant’s home or place of work). All IDIs and FGDs were audio-recorded, then translated and transcribed into French. The ANC observations were conducted in order to characterize the context and processes of IPTp-SP administration at each health center. Based on pre-testing, we determined that with two data collectors and a purposive sample five patients per center, we could produce a thorough and internally consistent description of that health center’s processes. The purposive sampling was intended to capture women at different points in their pregnancy. Data collectors observed each participant for the entirety of her ANC visit and completed a structured observation form covering the patient-provider interaction, clinical exam, content of patient counseling, and acquisition/administration of pharmaceuticals. Researchers also took unstructured notes detailing the events and context of the visit. Additionally, we reviewed maternity and pharmacy record books at each health center for SP stock and distribution information. Analysis of textual and observational data was an iterative, collaborative process. Interviewers wrote reflective memos after each data collection session and discussed developing themes at regular debriefing meetings [27]. Throughout data collection, we added and adjusted questions on IDI and FGD guides based on previous IDIs, FGDs, and debriefings. Transcripts and observation notes were uploaded into ATLAS.ti version 7 for descriptive coding [28]. The research team began coding inductively and periodically revised the codebook as new themes emerged. A sample of transcripts were double-coded to ensure consistency between researchers. Multiple members of the research team reviewed and discussed data outputs of each code to summarize findings. The Institutional Review Boards of the Johns Hopkins Bloomberg School of Public Health and the Faculty of Medicine, Pharmacy, and Odontostomatology at the University of Sciences, Techniques, and Technologies of Bamako approved the study. Informed consent was obtained from all participants of IDIs, FGDs and observations. Interviewers signed consent forms to document oral consent, which was collected in order to overcome literacy limitations and ensure participant anonymity.

Based on the information provided, here are some potential innovations that could improve access to maternal health in Mali:

1. Mobile Health (mHealth) Solutions: Develop mobile applications or SMS-based systems to send reminders and educational messages to pregnant women about the importance of attending antenatal care (ANC) visits and taking medications like IPTp-SP. These solutions can also provide information on the nearest health centers and their services.

2. Community Health Workers (CHWs): Train and deploy CHWs in rural areas to provide education and counseling on maternal health, including the benefits of IPTp-SP. CHWs can also conduct home visits to reach women who may not be able to attend ANC visits regularly.

3. Task Shifting: Train and empower nurses and midwives to administer IPTp-SP during ANC visits, following up-to-date guidelines. This can help increase the availability and accessibility of IPTp-SP, especially in areas where there is a shortage of doctors.

4. Free or Subsidized IPTp-SP: Advocate for policies that ensure IPTp-SP is provided free of charge or at a subsidized cost to pregnant women. This can help reduce cost barriers and increase uptake.

5. Improved Patient Counseling: Strengthen patient counseling during ANC visits to ensure pregnant women understand the purpose and benefits of IPTp-SP. This can help improve accuracy in reporting and increase acceptance of the medication.

6. Strengthen Health System: Address health system factors that contribute to missed opportunities for IPTp-SP uptake, such as inconsistent administration practices and stockouts of SP. This can be done through training, supervision, and monitoring of health center staff.

7. Data Quality Improvement: Improve data collection and reporting systems to ensure accurate and complete data on IPTp-SP coverage. This can help identify gaps and monitor progress in increasing access to maternal health services.

These innovations, if implemented effectively, have the potential to improve access to maternal health, increase IPTp-SP uptake, and ultimately reduce the burden of malaria in pregnancy in Mali.
AI Innovations Description
Based on the information provided, the following recommendation can be developed into an innovation to improve access to maternal health:

1. Increasing ANC Attendance: The first priority for increasing IPTp-SP coverage is to increase attendance at antenatal care (ANC) visits. This can be achieved by implementing innovative strategies such as mobile clinics, community outreach programs, and incentives for pregnant women to attend ANC visits regularly.

2. Reducing Cost and Access Barriers: To improve access to maternal health services, it is important to reduce cost and access barriers. This can be done by providing IPTp-SP free of charge to pregnant women, especially in rural areas where access to healthcare facilities may be limited.

3. Ensuring Providers Follow Up-to-Date Guidelines: Health centers should be encouraged to follow up-to-date guidelines for administering IPTp-SP. This includes providing IPTp-SP through directly observed therapy and giving it at one-month intervals during the second and third trimesters of pregnancy.

4. Improving Patient Counseling: Patient counseling on IPTp-SP should be improved to ensure that pregnant women understand the importance of taking the medication and its purpose. This can be done through training healthcare providers to effectively communicate with pregnant women and provide clear and accurate information about IPTp-SP.

By implementing these recommendations, access to maternal health can be improved, leading to increased uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) in rural Mali.
AI Innovations Methodology
Based on the information provided, here are some potential recommendations to improve access to maternal health in Mali:

1. Increase ANC attendance: Since the majority of women who did not receive IPTp-SP also did not attend ANC, increasing ANC attendance should be a priority. This can be achieved through community awareness campaigns, improving transportation infrastructure, and providing incentives for women to attend ANC visits.

2. Reduce cost and access barriers: Cost and access barriers were identified as factors contributing to low uptake of IPTp-SP. To address this, measures can be taken to reduce the cost of ANC visits and IPTp-SP, such as subsidizing or providing IPTp-SP free of charge. Additionally, efforts can be made to improve the availability and accessibility of ANC services in rural areas.

3. Ensure adherence to guidelines: The qualitative data revealed that many health centers did not follow the recommended guidelines for administering IPTp-SP. It is important to ensure that healthcare providers are trained and equipped to administer IPTp-SP according to the recommended protocols. Regular monitoring and supervision can help ensure adherence to guidelines.

4. Improve patient counseling: The study found that women frequently could not identify the name or purpose of IPTp-SP, potentially affecting the accuracy of responses in household surveys. Improving patient counseling on IPTp-SP can help increase awareness and understanding among pregnant women. This can be done through training healthcare providers on effective counseling techniques and providing educational materials for pregnant women.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could be developed using the following steps:

1. Define the indicators: Identify specific indicators that measure access to maternal health, such as ANC attendance rates, IPTp-SP coverage, and knowledge about IPTp-SP.

2. Collect baseline data: Gather data on the current status of the indicators before implementing the recommendations. This can be done through surveys, interviews, and data analysis of existing datasets, such as the Mali DHS maternal health dataset.

3. Implement the recommendations: Put the recommendations into action, such as conducting community awareness campaigns, providing subsidies for ANC visits and IPTp-SP, training healthcare providers, and improving patient counseling.

4. Monitor and evaluate: Continuously monitor the implementation of the recommendations and collect data on the indicators. This can be done through surveys, interviews, and data analysis. Compare the data to the baseline data to assess the impact of the recommendations on improving access to maternal health.

5. Analyze the data: Use statistical analysis techniques to analyze the data and determine the extent to which the recommendations have improved access to maternal health. This can involve comparing pre- and post-intervention data, conducting regression analysis, and calculating effect sizes.

6. Draw conclusions and make recommendations: Based on the analysis of the data, draw conclusions about the impact of the recommendations on improving access to maternal health. Identify any gaps or areas for further improvement and make recommendations for future interventions.

It is important to note that the specific methodology for simulating the impact of these recommendations may vary depending on the available data, resources, and context.

Yabelana ngalokhu:
Facebook
Twitter
LinkedIn
WhatsApp
Email